Self-screen is constantly developing novel state-of-the-art clinical tests for (early) cancer detection. These tests meet growing requirements in both primary screening as well as triage settings.
This could be in terms of terms of validation of certain sample types, such as existing cytology preservatives, or other media, or for instance new sample types such as self sampling (validations for different devices) or for instance urine. Other developments ongoing are intended use extensions, as is for instance the occasion for methylation assays. Such developments could be in the direction of the discovery and validation of new marker sets for improved clinical performance, or in adjacent HPV driven disease area’s (e.g. anal cancer, endometrium cancer….). In addition validation on various commercial PCR platforms is also part of our offering.
Our development offerings
Should you have any projects in mind where Self-screen may offer its expertise and support please contact us for further information at email@example.com.